.jpg?format=webp&width=780)
The U.S. FDA approves Ixchiq, the first chikungunya vaccine for those aged 18 and above at risk of exposure. Chikungunya, transmitted by infected mosquitoes, poses a global health threat, with over 5 million cases reported in the last 15 years. Symptoms include fever, joint pain, rash, and headache. Ixchiq, administered as a single dose, contains a weakened virus. Clinical studies showed common side effects like headache and muscle pain. Severe reactions occurred in 1.6% of recipients, leading to hospitalization.
Like
Save
Share